Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion - WSJ
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion WSJBiogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outloo...
Source: news.google.com
Biogen to Acquire Apellis Pharmaceuticals for $5.6 Billion WSJBiogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology BiogenBiogen to buy Apellis Pharmaceuticals for $5.6 billion in rare disease push CNBCBiogen makes $5.6B bet on Apellis Pharma AxiosBiogen, eyeing swift commercial tailwind, ponies up $5.6B for Apellis and its 2 approved meds Fierce Pharma
